Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Ensuring Safe Transfusion Practices through Haemovigilance: India vis-a-vis Global Scenario

Author(s): Ruhi Rana, Sastha Ram Veluri Kishore, Gagandeep Kaur, Gurvinder Singh and Rajesh Kumar*

Volume 18, Issue 4, 2023

Published on: 09 January, 2023

Page: [474 - 483] Pages: 10

DOI: 10.2174/1574886318666221206114638

Price: $65

Abstract

Haemovigilance is the monitoring of the essential components of blood transfusion from its initial stages to the final outcome considering all the safety parameters and hazards that co-exist with it. It primarily aims to ensure the quality as well as safety related to the use of blood and blood products utilizing the standard healthcare framework and a tailored vigilance program for efficient outcomes. Initially, the art of vigilance was started with the therapeutic products available in the market giving some groundbreaking data on their safety which later led to the implementation of timely measures to control adverse events significantly. Several incidents have occurred during the collection, transport, storage, and transfusion of blood and to stop these incidences of hazard, haemovigilance came into existence with France becoming the first country to step in followed by several nations across the world with customized guidelines directing it to the best. The majorly reported problems include bacterial infections, hemolytic and immune reactions. The present writeup reviews the inception and development of haemovigilance programs with a global scenario, a detailed study of the haemovigilance program adopted in India, and the updated status of these programs in various countries across the globe.

Keywords: Haemovigilance, blood transfusion, bacterial infection, Hemo-Vigil, RBCs, SHOT.

« Previous Next »
Graphical Abstract

[1]
Arslan O. Haemovigilance in developing countries. Hematology 2005; 10(S1): 79-81.
[http://dx.doi.org/10.1080/10245330512331389728]
[2]
Faber JC. Hemovigilance: Definition and overview of current hemovigilance systems. Transfus Altern Transfus Med 2003; 5(1): 237-45.
[http://dx.doi.org/10.1111/j.1778-428X.2003.tb00157.x]
[3]
Wood EM, Ang AL, Bisht A, et al. International haemovigilance: what have we learned and what do we need to do next? Transfus Med 2019; 29(4): 221-30.
[http://dx.doi.org/10.1111/tme.12582] [PMID: 30729612]
[4]
Marwaha N, Singh S, Bisht A. Setting up haemovigilance from the very first step. The Indian perspective. ISBT Sci Ser 2014; 9(1): 178-83.
[http://dx.doi.org/10.1111/voxs.12084]
[5]
Faber JC. Work of the European haemovigilance network (EHN). Transfus Clin Biol 2004; 11(1): 2-10.
[http://dx.doi.org/10.1016/j.tracli.2003.11.001] [PMID: 14980542]
[6]
de Vries RRP. Haemovigilance: recent achievements and developments in the near future. ISBT Sci Ser 2009; 4(1): 60-2.
[http://dx.doi.org/10.1111/j.1751-2824.2009.01227.x]
[7]
Engelfriet CP, Reesink HW, Brand B, et al. Haemovigilance Systems. Vox Sang 1999; 77(2): 110-1.
[http://dx.doi.org/10.1046/j.1423-0410.1999.77201101.x] [PMID: 10577259]
[8]
Kapoor D, Dadarwal D, Vyas R. An overview on haemovigilance: Part of pharmacovigilance. Int J Pharm Pharmacol 2018; 2(1): 1-5.
[9]
de Vries RRP, Faber JC, Strengers PFW. Haemovigilance: An effective tool for improving transfusion practice. Vox Sang 2011; 100(1): 60-7.
[http://dx.doi.org/10.1111/j.1423-0410.2010.01442.x] [PMID: 21175656]
[10]
Flesland O, Wiersum-Osselton JC. Donor vigilance and hemovigilance. Rossi’s principles of transfusion medicine. Chichester. In: Wiley Blackwell: New Jersey 2016; pp. 58-68.
[http://dx.doi.org/10.1002/9781119013020.ch06]
[11]
Rossi U. Basic clinical and organizational requirements for an effective haemovigilance. Luki L, Brubnjak-Jevti V, Primoži J, Benedik-Dolni M, Rossi U. Blood therapy in Neonatology and Paediatrics Haemovigilance Proceedings Slovenian/ESTM residential course (5th Postgraduate course on “Blood safety and surgery”),. Portorož (Slovenia). 2002; pp. 12-4.
[12]
Debeir J, Noel L, Aullen JP, et al. The French haemovigilance system. Vox Sang 1999; 77(2): 77-81.
[http://dx.doi.org/10.1046/j.1423-0410.1999.7720077.x] [PMID: 10516551]
[13]
Tutu EK. A review of international blood safety and quality regulations: Key implications for blood organizations and hospital blood transfusion practice. Canadian J Med Lab Sci 2011; 73(4): 6.
[14]
Kalaiselvan V, Thota P, Singh G. Pharmacovigilance programme of India: Recent developments and future perspectives. Indian J Pharmacol 2016; 48(6): 624-8.
[http://dx.doi.org/10.4103/0253-7613.194855] [PMID: 28066097]
[15]
Morel P, Hervé P. Surveillance of blood transfusion safety: Contribution of the hemovigilance strategy in France. Transfus Med Rev 1998; 12(2): 109-27.
[http://dx.doi.org/10.1016/S0887-7963(98)80033-3] [PMID: 9566078]
[16]
Williamson LM. Using haemovigilance data to set blood safety priorities. Vox Sang 2002; 83(S1): 65-9.
[http://dx.doi.org/10.1111/j.1423-0410.2002.tb05270.x] [PMID: 12617106]
[17]
De Vries RR, Faber JC. Hemovigilance: An effective tool for improving transfusion safety. John Wiley & Sons 2012.
[http://dx.doi.org/10.1002/9781118338179]
[18]
Faber JC. Worldwide overview of existing haemovigilance systems. Transfus Apheresis Sci 2004; 31(2): 99-110.
[http://dx.doi.org/10.1016/j.transci.2004.07.004] [PMID: 15501414]
[19]
Cabedal MCL. Hemoterapia e hemovigilância. 2019. Available from: https://repositorio.ul.pt/bitstream/10451/36028/1/MICF_Ines_Caxaria.pdf
[20]
Boparai J, Singh S. Hemovigilance: A new beginning in India. Int J Appl Basic Med Res 2015; 5(3): 200-2.
[http://dx.doi.org/10.4103/2229-516X.165379] [PMID: 26539371]
[21]
Vasudev R. The Indian Hemovilance System: The Challenges Ahead. JK Science 2015; 17(2): 108.
[22]
Bisht A, Singh S, Marwaha N. Hemovigilance program-India. Asian J Transfus Sci 2013; 7(1): 73-4.
[http://dx.doi.org/10.4103/0973-6247.106744] [PMID: 23559771]
[23]
Mukherjee S, Maiti R. Haemovigilance: A current update in Indian perspective. J Clin Diagn Res 2016; 10(11): EE05-9.
[http://dx.doi.org/10.7860/JCDR/2016/21029.8868] [PMID: 28050389]
[24]
Bisht A, Marwaha N, Kaur R, Gupta D, Chhabra R. Haemovigilance programme of India: Comparative analysis of transfusion reactions reported over a 5-year period through two reporting formats and key recommendations for blood safety. Asian J Transfus Sci 2020; 14(2): 103-16.
[http://dx.doi.org/10.4103/ajts.ajts_192_20] [PMID: 33767535]
[25]
Dutta A, Chaudhry S, Banerjee A. Hemovigilance in India: Corrective action towards safety of blood transfusion. J Preventive Med Holistic Health 2021; 6(2): 66-71.
[http://dx.doi.org/10.18231/j.jpmhh.2020.013]
[26]
Ayob Y. Hemovigilance in developing countries. Biologicals 2010; 38(1): 91-6.
[http://dx.doi.org/10.1016/j.biologicals.2009.10.002] [PMID: 20133151]
[27]
Menitove J E. Hemovigilance in the United States of America. Vox Sang 1998; 74(S2): 447-55.
[28]
Bisht A, Marwaha N, Kaur R, Gupta D, Singh S. Haemovigilance programme of India: Analysis of transfusion reactions reported from January 2013 to April 2016 and key recommendations for blood safety. Asian J Transfus Sci 2018; 12(1): 1-7.
[http://dx.doi.org/10.4103/ajts.AJTS_5_18] [PMID: 29563667]
[29]
de Jonge LL, Wiersum-Osselton JC, Bokhorst AG, Schipperus MR, Zwaginga JJ. Haemovigilance: Current practices and future developments. 2022.
[http://dx.doi.org/10.21037/aob-22-2]
[30]
Vlaar APJ, Juffermans NP. Transfusion-related acute lung injury: a clinical review. Lancet 2013; 382(9896): 984-94.
[http://dx.doi.org/10.1016/S0140-6736(12)62197-7] [PMID: 23642914]
[31]
Bolton-Maggs PHB. Serious hazards of transfusion - conference report: Celebration of 20 years of UK haemovigilance. Transfus Med 2017; 27(6): 393-400.
[http://dx.doi.org/10.1111/tme.12502] [PMID: 29282809]
[32]
Godbey EA, Thibodeaux SR. Ensuring safety of the blood supply in the United States: Donor screening, testing, emerging pathogens, and pathogen inactivation. In: Seminars in hematology. Elsevier: Amsterdam 2019; pp. 229-35.
[33]
Cho JH, Rajbhandary S, Buren NL, et al. The safety of COVID ‐19 convalescent plasma donation: A multi‐institutional donor hemovigilance study. Transfusion 2021; 61(9): 2668-76.
[http://dx.doi.org/10.1111/trf.16572] [PMID: 34227689]
[34]
Faber DJC. Haemovigilance around the world. Vox Sang 2002; 83(S1): 71-6.
[http://dx.doi.org/10.1111/j.1423-0410.2002.tb05271.x] [PMID: 12617107]
[35]
Xie D, Zhu Y. Haemovigilance in China: Experiences, challenges and strategies. ISBT Sci Ser 2018; 13(3): 302-5.
[http://dx.doi.org/10.1111/voxs.12424]
[36]
Tian X, Kong Y, Wang J, et al. Development of the Chinese Haemovigilance Network and reporting of adverse transfusion reactions from 2018 to 2020. Vox Sang 2022; 117(8): 1027-34.
[http://dx.doi.org/10.1111/vox.13291] [PMID: 35560059]
[37]
Strengers P. What is haemovigilance? The European Haemovigilance Network (EHN). Proceedings of the ESTM residential course: Basic clinical and organisational requirements for an effective haemovigilance Sofia. Transfus Clin Biol 2001; 28(30): 11.

Rights & Permissions Print Cite
Article Metrics
25
2
© 2024 Bentham Science Publishers | Privacy Policy